Genital PRP and Mesotherapy in Ordu

PRP preparation and composition can vary between procedures. Being derived from the person’s blood does not make an injection free of risk. Mesotherapy additionally requires clarity about the substances and mixture used.

Findings from a PRP study cannot be transferred to a different mesotherapy mixture. Research in skin or hair applications does not establish the same benefit in genital tissue. Each proposal needs a clear target tissue and purpose.

A small randomised pilot trial published in 2026 reported improvement in some measures after vaginal PRP in premenopausal participants without severe sexual dysfunction. It included 52 participants and six months of follow-up. This does not establish definite benefit across all ages, sexual concerns or longer periods.

In a separate placebo-controlled trial for stress urinary incontinence, one PRP injection did not significantly outperform saline for treatment success. Results need interpretation for the specific condition and protocol. They do not establish one universal dose, session schedule or permanent success claim.

Dryness, pain, urinary leakage and orgasm difficulties may have different causes. Established options for vaginal dryness should not be presented as equivalent to investigational approaches. Preferring to avoid hormones does not automatically make PRP appropriate.

For sexual concerns, orgasm and sexual wellbeing assessment considers physical and psychosocial factors together. Urinary incontinence care may involve rehabilitation, medicines or surgery according to leakage type. Choosing an injection cannot replace a diagnosis.

Pain, bruising, bleeding, infection and tissue reactions may occur. Mesotherapy can also cause allergy or other effects related to its ingredients. Blood-thinning medicines, bleeding problems, active infection and earlier reactions need consideration.

Uncertainty about benefit, alternatives and the option of no procedure should be explicit. No serious adverse event in one study does not rule out uncommon or delayed risks. Increasing pain, fever, marked swelling or discharge after treatment requires assessment.

Bring details of previous treatments and products to the consultation in Fatsa. Discuss the research supporting the proposal, how it relates to your goal and follow-up needs. For people travelling from elsewhere in Ordu, a review plan is more useful than a promised number of sessions.

Genital PRP and mesotherapy differ in their composition and evidence. New research warrants careful attention, but small studies cannot establish universal outcomes. Diagnosis, established alternatives and injection risks remain central.